Johnson & Johnson COVID-19 vaccine 66% effective in global trial, company says

Johnson & Johnson on Friday said its single-shot coronavirus vaccine was 72% effective in preventing moderate-to-severe COVID-19 in the U.S, but fell to 66% in a larger trial conducted worldwide.